Abstract
We have discovered a new short acting bronchodilator represents a new class of bronchodilator. The drug, S-1226, is made up of a gas (4-12% CO2 in air) combined with a synthetic lung surfactant, perflubron, delivered as a nebulized mixture of perflubron vapour and perflubron aerosol, within the CO2 gas. We have demonstrated rapid broncho-dilatation via a unique mechanism of action that is neither adrenergic or cholinergic. We suspect the bronchodilator effect of the drug is mediated by epithelial receptors and vagal C-fibres and sustained by the biophysical action of perflubron and its interaction with natural lung surfactants.
Bronchodilation is shown in animal models to be very rapid within 4 seconds and more rapid and prolonged than seen with conventional rapid acting adrenergic (salbutamol) drugs and their analogs in animal models.
S-1226 has completed Phase I in humans and is currently undergoing Phase II clinical trails to provide proof of concept for safety and efficacy in human asthmatics.
Given it's unique biophysical mechanism, S-1226 represents a new class of bronchodilator drug. S-1226 will have clinical relevance when existing drugs fail.
www.solaeromed.com
- Copyright ©ERS 2015
